Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Rabin

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In VivoNicola M G Smith, Petra Mlcochova, Sarah A Watters, et al.
Bone Marrow Transplantation|July 30, 2025
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMTSimona Iacobelli, Stefan Schönland, Linda Koster, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 18, 2015
Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In VivoNicola M G Smith, Petra Mlcochova, Sarah A Watters, et al.
Bone Marrow Transplantation|July 30, 2025
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMTSimona Iacobelli, Stefan Schönland, Linda Koster, et al.
The New England Journal of Medicine|October 6, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaMeletios A Dimopoulos, Albert Oriol, Hareth Nahi, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
British Journal of Haematology|November 11, 2021
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapyStephen Booth, Helen M Curley, Csilla Varnai, et al.
Pageof 8